

# Mark E Dunlap

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10971672/publications.pdf>

Version: 2024-02-01

39  
papers

2,404  
citations

279798

23  
h-index

330143

37  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3358  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction. <i>Circulation</i> , 2004, 110, 2618-2626.	1.6	347
2	Sympathetically Mediated Changes in Capacitance. <i>Circulation: Heart Failure</i> , 2011, 4, 669-675.	3.9	251
3	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. <i>Circulation</i> , 2015, 131, 1763-1771.	1.6	239
4	Pulsatile Hemodynamics in Congestive Heart Failure. <i>Hypertension</i> , 2001, 38, 1433-1439.	2.7	183
5	Incidence and Predictors of Hyperkalemia in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1959-1966.	2.8	153
6	Aortic Diameter, Wall Stiffness, and Wave Reflection in Systolic Hypertension. <i>Hypertension</i> , 2008, 51, 105-111.	2.7	151
7	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)â€“Added trial. <i>American Heart Journal</i> , 2006, 151, 985-991.	2.7	102
8	Long-Term Trandolapril Treatment Is Associated With Reduced Aortic Stiffness. <i>Hypertension</i> , 2007, 49, 1271-1277.	2.7	102
9	Ganglionic Mechanisms Contribute to Diminished Vagal Control in Heart Failure. <i>Circulation</i> , 1999, 99, 2958-2963.	1.6	97
10	Evidence for impaired vagus nerve activity in heart failure. <i>Heart Failure Reviews</i> , 2011, 16, 129-135.	3.9	88
11	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	4.1	84
12	Functional Nicotinic Acetylcholine Receptors That Mediate Ganglionic Transmission in Cardiac Parasympathetic Neurons. <i>Journal of Neuroscience</i> , 2000, 20, 5076-5082.	3.6	67
13	Changes in Aortic Stiffness and Augmentation Index After Acute Converting Enzyme or Vasopeptidase Inhibition. <i>Hypertension</i> , 2005, 46, 1111-1117.	2.7	65
14	Augmentation Index and Central Aortic Stiffness in Middle-Aged to Elderly Individuals. <i>American Journal of Hypertension</i> , 2007, 20, 642-647.	2.0	62
15	Impact of Statin Use After Heart Transplantation. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	55
16	Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2003, 285, H1632-H1640.	3.2	53
17	Interactive effects of hypoxia, hypercapnia and lung volume on sympathetic nerve activity in humans. <i>Experimental Physiology</i> , 2015, 100, 1018-1029.	2.0	47
18	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021, 23, 1076-1084.	7.1	37

#	ARTICLE	IF	CITATIONS
19	Extracardiac Abnormalities of Preload Reserve. <i>Circulation: Heart Failure</i> , 2021, 14, e007308.	3.9	33
20	Prevention of diminished parasympathetic control of the heart in experimental heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H1780-H1785.	3.2	32
21	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq1 1 0.784314 rgBT /Over	1.6	26
22	Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: The CHARM Program. <i>European Journal of Heart Failure</i> , 2006, 8, 191-197.	7.1	24
23	Chemohypersensitivity and Autonomic Modulation of Venous Capacitance in the Pathophysiology of Acute Decompensated Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 139-146.	3.3	24
24	Fluid Re-Distribution Rather Than Accumulation Causes Most Cases of Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 165-166.	2.8	22
25	$\beta_7$ -Nicotinic acetylcholine receptor subunit is not required for parasympathetic control of the heart in the mouse. <i>Physiological Genomics</i> , 2005, 22, 86-92.	2.3	17
26	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Academic Emergency Medicine</i> , 2016, 23, 922-931.	1.8	10
27	New Studies Influencing Treatment of Heart Failure: 2006 Update. <i>Pharmacotherapy</i> , 2007, 27, 3S-11S.	2.6	5
28	Autonomic Modulation in Heart Failure: Ready for Prime Time?. <i>Current Cardiology Reports</i> , 2015, 17, 103.	2.9	5
29	Cardiopulmonary Baroreflex Control of Renal Sympathetic Nerve Activity Is Impaired in Dogs With Left Ventricular Dysfunction. <i>Journal of Cardiac Failure</i> , 2019, 25, 819-827.	1.7	5
30	Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. <i>Journal of Cardiac Failure</i> , 2016, 22, 618-627.	1.7	4
31	Heart Failure Notwithstanding Ejection Fraction (HF <sub>NEF</sub> )—A Possible Unifying Hypothesis?. <i>Journal of Cardiac Failure</i> , 2014, 20, 60-62.	1.7	3
32	Autonomic Dysregulation as a Therapeutic Target for Acute HF. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2015, 17, 403.	0.9	3
33	Measuring Congestion in Acute Heart Failure: The “Holy Grail” Still Awaits. <i>Journal of Cardiac Failure</i> , 2016, 22, 689-691.	1.7	3
34	Combination pharmacologic therapies for heart failure: What next after angiotensin-converting enzyme inhibitors and beta-blockers?. <i>Current Heart Failure Reports</i> , 2005, 2, 89-93.	3.3	2
35	Management of heart failure with pulmonary hypertension. <i>Current Cardiology Reports</i> , 2005, 7, 196-203.	2.9	1
36	Efficiently Doing the Wrong Thing. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1713.	2.8	1

#	ARTICLE	IF	CITATIONS
37	â€œI've Had a Good Runâ€ Journal of Cardiac Failure, 2021, 27, 1290.	1.7	1
38	Response to Wave Reflection in Systolic Hypertension: Smaller Stature, Shorter Aorta: Higher Pulse Pressure? and Questions Regarding the Aortic Measurements of Mitchell et al. Hypertension, 2008, 51, .	2.7	0
39	Pathophysiology of Cardio-Renal Syndrome: Autonomic Mechanisms. , 2020, , 35-50.		0